# Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux Disease

> **NCT07160790** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Onconic Therapeutics Inc.** · enrollment: 321 (estimated)

## Conditions studied

- Non-erosive Gastroesophageal Reflux Disease

## Interventions

- **DRUG:** JP-1366 + placebo
- **DRUG:** Placebo + Placebo

## Key facts

- **NCT ID:** NCT07160790
- **Lead sponsor:** Onconic Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-02
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 321 (ESTIMATED)
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07160790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07160790, "Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07160790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*